Gastrointestinal Therapeutics Market Share Analysis Report, 2023-2032
The global gastrointestinal therapeutics market size was exhibited at USD 37.9 billion in 2022 and is projected to hit around USD 52.95 billion by 2032, growing at a CAGR of 3.4% during the forecast period 2023 to 2032.
Key Pointers:
Gastrointestinal Therapeutics Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 39.19 Billion |
|
Market Size by 2032 |
USD 52.95 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 3.4% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Type, Drug class, Application, Distribution channel, Route of administration |
|
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key companies profiled |
AbbVie Inc.; AstraZeneca; Janssen Pharmaceuticals NV; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited; Salix Pharmaceuticals; Pfizer Inc.; Bayer AG; Abbott; Cipla Inc.; Gilead Sciences, Inc.; Biogen; Organon Group of Companies |
Unhealthy eating habits, coupled with a sedentary lifestyle, have led to the development of gastrointestinal diseases among consumers, which is expected to drive market growth. Moreover, the rising adoption of biologics for the treatment of GI disorders is also fueling growth. For instance, REMICADE (Infliximab) by Janssen Biotech, Inc., and other biological drugs have been approved for the treatment of Crohn’s disease and ulcerative colitis.
The increasing incidences of industry-academia collaborations to promote gastrointestinal research and develop novel therapies for patients with GI disorders will likely facilitate market expansion. For instance, in November 2020, Takeda Pharmaceutical Company Limited, Columbia University, and New York University formed a collaborative research alliance to advance gastroenterology research programs, to develop new therapeutics for gastrointestinal diseases.
Moreover, market growth is also anticipated to increase research & development initiatives by government and private organizations for the development of new gastrointestinal drugs. As of November 2022, according to the U.S. National Library of Medicine, there were 7,586 ongoing clinical studies (including observational studies, drug development, and others) related to gastrointestinal diseases, at various stages of development. Moreover, in May 2022, AbbVie Inc. announced positive topline results from a phase-3 study that is evaluating upadacitinib in adult patients with severe to moderate Crohn's disease, who were intolerant to biologic therapy.
The presence of government and non-profit organizations that support gastrointestinal research, offer to fund studies, and promote awareness about GI disorders, is anticipated to augment GI therapeutics market growth. For instance, the International Foundation for Gastrointestinal Disorders, GI- research foundation, and American Gastroenterological Association are some of the key organizations supporting research activities and increasing awareness about gastrointestinal diseases among people. These organizations also raise funds for ongoing GI research activities.
Furthermore, various strategic initiatives such as product launches, collaboration, mergers, and acquisitions undertaken by leading players are expected to offer lucrative opportunities for market growth. For instance, in July 2022, Eli Lilly announced a partnership with the Chinese drug 3D printing firm to develop and research 3D-printed oral drugs for the GI tract application.
In addition, in April 2020acquired global rights, excluding Canada, Europe, and Israel, of Movantik (naloxegol) by AstraZeneca, for the management of opioid-induced constipation. This acquisition is expected to strengthen the company’s position in the global gastrointestinal therapeutics industry.
Some of the prominent players in the Gastrointestinal Therapeutics Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Gastrointestinal Therapeutics market.
By Type
By Drug Class
By Route of Administration
By Application
By Distribution Channel
By Region
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 Nova one advisor’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Competitive Insights
Chapter 3 Gastrointestinal Therapeutics Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Increase in development of biologics
3.2.1.2 High prevalence of gastrointestinal disorders
3.2.2 Market restraint analysis
3.2.2.1 High number of patent expirations
3.3 Penetration & Growth Prospect Mapping
3.4 Gastrointestinal Therapeutics: Market Analysis Tools
3.4.1 Industry analysis - Porter’s Five Forces
3.4.2 PESTLE analysis
3.5 Regulatory Framework
3.6 Pricing Analysis
Chapter 4 Gastrointestinal Therapeutics Market Segment Analysis, By Type, 2020 - 2032
4.1 Definition and Scope
4.2 Type Market Share Analysis, 2023 & 2032
4.3 Segment Dashboard
4.4 Global Gastrointestinal Therapeutics Market, by Type, 2020 to 2032
4.5 Market Size & Forecasts and Trend Analyses, 2020 to 2032
4.5.1 Branded
4.5.1.1 Branded market estimates and forecast, 2020 - 2032
4.5.2 Generic
4.5.2.1 Generic market estimates and forecast, 2020 - 2032
Chapter 5 Gastrointestinal Therapeutics Market Segment Analysis, By Drug Class 2020 - 2032
5.1 Definition and Scope
5.2 Drug Class Market Share Analysis, 2023 & 2032
5.3 Segment Dashboard
5.4 Global Gastrointestinal Therapeutics Market, by Drug Class, 2020 to 2032
5.5 Market Size & Forecasts and Trend Analyses, 2020 to 2032
5.5.1 Aminosalicylates
5.5.1.1 Aminosalicylates market estimates and forecast, 2020 - 2032
5.5.2 Digestive enzymes
5.5.2.1 Digestive enzymes market estimates and forecast, 2020 - 2032
5.5.3 Proton pump inhibitors
5.5.3.1 Proton pump inhibitors market estimates and forecast, 2020 - 2032
5.5.4 Laxatives
5.5.4.1 Laxatives market estimates and forecast, 2020 - 2032
5.5.5 Anti-emetics
5.5.5.1 Anti-emetics market estimates and forecast, 2020 - 2032
5.5.6 H2 antagonists
5.5.6.1 H2 antagonists market estimates and forecast, 2020 - 2032
5.5.7 Anti-diarrheal
5.5.7.1 Anti-diarrheal market estimates and forecast, 2020 - 2032
5.5.8 Biologics/Biosimilar
5.5.8.1 Biologics/Biosimilar market estimates and forecast, 2020 - 2032
5.5.9 Others
5.5.9.1 Others market estimates and forecast, 2020 - 2032
Chapter 6 Gastrointestinal Therapeutics Market Segment Analysis, By Route of Administration, 2020 - 2032
6.1 Definition and Scope
6.2 Route of Administration Market Share Analysis, 2023 & 2032
6.3 Segment Dashboard
6.4 Global Gastrointestinal Therapeutics Market, by Route of Administration, 2020 to 2032
6.5 Market Size & Forecasts and Trend Analyses, 2020 to 2032
6.5.1 Oral
6.5.1.1 Oral market estimates and forecast, 2020 - 2032
6.5.2 Injectable
6.5.2.1 Injectable market estimates and forecast, 2020 - 2032
6.5.3 Others
6.5.3.1 Others market estimates and forecast, 2020 - 2032
Chapter 7 Gastrointestinal Therapeutics Market Segment Analysis, By Application, 2020 - 2032
7.1 Definition and Scope
7.2 Application Market Share Analysis, 2023 & 2032
7.3 Segment Dashboard
7.4 Global Gastrointestinal Therapeutics Market, by Application, 2020 to 2032
7.5 Market Size & Forecasts and Trend Analyses, 2020 to 2032
7.5.1 Crohn’s disease
7.5.1.1 Crohn’s disease market estimates and forecast, 2020 - 2032 (Number of Patients by Type in Million)
7.5.2 Ulcerative colitis
7.5.2.1 Ulcerative colitis market estimates and forecast, 2020 - 2032 (Number of Patients by Type in Million)
7.5.3 GERD
7.5.3.1 GERD market estimates and forecast, 2020 - 2032 (Number of Patients by Type in Million)
7.5.4 IBS
7.5.4.1 IBS market estimates and forecast, 2020 - 2032 (Number of Patients by Type in Million)
7.5.5 Others
7.5.5.1 Others market estimates and forecast, 2020 - 2032 (Number of Patients by Type in Million)
Chapter 8 Gastrointestinal Therapeutics Market Segment Analysis, By Distribution channel, 2020 - 2032
8.1 Definition and Scope
8.2 Distribution Channel Market Share Analysis, 2023 & 2032
8.3 Segment Dashboard
8.4 Global Gastrointestinal Therapeutics Market, by Distribution Channel, 2020 to 2032
8.5 Market Size & Forecasts and Trend Analyses, 2020 to 2032
8.5.1 Hospital pharmacies
8.5.1.1 Hospital pharmacies market estimates and forecast, 2020 - 2032
8.5.2 Retail pharmacies
8.5.2.1 Retail pharmacies market estimates and forecast, 2020 - 2032
8.5.3 Online pharmacies
8.5.3.1 Online pharmacies market estimates and forecast, 2020 - 2032
Chapter 9 Gastrointestinal Therapeutics Market Segment Analysis, By Region, 2020 - 2032 (Number of Patients by Type in Million)
9.1 Definition & Scope
9.2 Regional Market Share Analysis, 2023 & 2032
9.3 Regional Market Dashboard
9.4 Regional Market Snapshot
9.5 SWOT Analysis
9.5.1 North America
9.5.2 Europe
9.5.3 Asia Pacific
9.5.4 Latin America
9.5.5 Middle East and Africa
9.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2023 to 2032
9.6.1 North America
9.6.1.1 North America gastrointestinal therapeutics market, 2020 - 2032 (Number of Patients by Type in Million)
9.6.1.2 U.S.
9.6.1.2.1 Key Country Dynamics
9.6.1.2.2 Competitive Scenario
9.6.1.2.3 Regulatory Framework
9.6.1.2.4 Reimbursement Scenario
9.6.1.2.5 U.S. market estimates and forecast, 2020 - 2032
9.6.1.3 Canada
9.6.1.3.1 Key Country Dynamics
9.6.1.3.2 Competitive Scenario
9.6.1.3.3 Regulatory Framework
9.6.1.3.4 Reimbursement Scenario
9.6.1.3.5 Canada market estimates and forecast, 2020 - 2032
9.6.2 Europe
9.6.2.1 Europe gastrointestinal therapeutics market, 2020 - 2032 (Number of Patients by Type in Million)
9.6.2.2 UK
9.6.2.2.1 Key Country Dynamics
9.6.2.2.2 Competitive Scenario
9.6.2.2.3 Regulatory Framework
9.6.2.2.4 Reimbursement Scenario
9.6.2.2.5 UK market estimates and forecast, 2020 - 2032
9.6.2.3 Germany
9.6.2.3.1 Key Country Dynamics
9.6.2.3.2 Competitive Scenario
9.6.2.3.3 Regulatory Framework
9.6.2.3.4 Reimbursement Scenario
9.6.2.3.5 Germany market estimates and forecast, 2020 - 2032
9.6.2.4 Spain
9.6.2.4.1 Key Country Dynamics
9.6.2.4.2 Competitive Scenario
9.6.2.4.3 Regulatory Framework
9.6.2.4.4 Reimbursement Scenario
9.6.2.4.5 Spain market estimates and forecast, 2020 - 2032
9.6.2.5 France
9.6.2.5.1 Key Country Dynamics
9.6.2.5.2 Competitive Scenario
9.6.2.5.3 Regulatory Framework
9.6.2.5.4 Reimbursement Scenario
9.6.2.5.5 France market estimates and forecast, 2020 - 2032
9.6.2.6 Italy
9.6.2.6.1 Key Country Dynamics
9.6.2.6.2 Competitive Scenario
9.6.2.6.3 Regulatory Framework
9.6.2.6.4 Reimbursement Scenario
9.6.2.6.5 Italy market estimates and forecast, 2020 - 2032
9.6.2.7 Denmark
9.6.2.7.1 Key Country Dynamics
9.6.2.7.2 Competitive Scenario
9.6.2.7.3 Regulatory Framework
9.6.2.7.4 Reimbursement Scenario
9.6.2.7.5 Denmark market estimates and forecast, 2020 - 2032
9.6.2.8 Sweden
9.6.2.8.1 Key Country Dynamics
9.6.2.8.2 Competitive Scenario
9.6.2.8.3 Regulatory Framework
9.6.2.8.4 Reimbursement Scenario
9.6.2.8.5 Sweden market estimates and forecast, 2020 - 2032
9.6.2.9 Norway
9.6.2.9.1 Key Country Dynamics
9.6.2.9.2 Competitive Scenario
9.6.2.9.3 Regulatory Framework
9.6.2.9.4 Reimbursement Scenario
9.6.2.9.5 Norway market estimates and forecast, 2020 - 2032
9.6.3 Asia Pacific
9.6.3.1 Asia Pacific gastrointestinal therapeutics market, 2020 - 2032 (Number of Patients by Type in Million)
9.6.3.2 Japan
9.6.3.2.1 Key Country Dynamics
9.6.3.2.2 Competitive Scenario
9.6.3.2.3 Regulatory Framework
9.6.3.2.4 Reimbursement Scenario
9.6.3.2.5 Japan market estimates and forecast, 2020 - 2032
9.6.3.3 China
9.6.3.3.1 Key Country Dynamics
9.6.3.3.2 Competitive Scenario
9.6.3.3.3 Regulatory Framework
9.6.3.3.4 Reimbursement Scenario
9.6.3.3.5 China market estimates and forecast, 2020 - 2032
9.6.3.4 India
9.6.3.4.1 Key Country Dynamics
9.6.3.4.2 Competitive Scenario
9.6.3.4.3 Regulatory Framework
9.6.3.4.4 Reimbursement Scenario
9.6.3.4.5 India market estimates and forecast, 2020 - 2032
9.6.3.5 South Korea
9.6.3.5.1 Key Country Dynamics
9.6.3.5.2 Competitive Scenario
9.6.3.5.3 Regulatory Framework
9.6.3.5.4 Reimbursement Scenario
9.6.3.5.5 South Korea market estimates and forecast, 2020 - 2032
9.6.3.6 Australia
9.6.3.6.1 Key Country Dynamics
9.6.3.6.2 Competitive Scenario
9.6.3.6.3 Regulatory Framework
9.6.3.6.4 Reimbursement Scenario
9.6.3.6.5 Australia market estimates and forecast, 2020 - 2032
9.6.3.7 Thailand
9.6.3.7.1 Key Country Dynamics
9.6.3.7.2 Competitive Scenario
9.6.3.7.3 Regulatory Framework
9.6.3.7.4 Reimbursement Scenario
9.6.3.7.5 Thailand market estimates and forecast, 2020 - 2032
9.6.4 Latin America
9.6.4.1 Latin America gastrointestinal therapeutics market, 2020 - 2032 (Number of Patients by Type in Million)
9.6.4.2 Brazil
9.6.4.2.1 Key Country Dynamics
9.6.4.2.2 Competitive Scenario
9.6.4.2.3 Regulatory Framework
9.6.4.2.4 Reimbursement Scenario
9.6.4.2.5 Brazil market estimates and forecast, 2020 - 2032
9.6.4.3 Mexico
9.6.4.3.1 Key Country Dynamics
9.6.4.3.2 Competitive Scenario
9.6.4.3.3 Regulatory Framework
9.6.4.3.4 Reimbursement Scenario
9.6.4.3.5 Mexico market estimates and forecast, 2020 - 2032
9.6.4.4 Argentina
9.6.4.4.1 Key Country Dynamics
9.6.4.4.2 Competitive Scenario
9.6.4.4.3 Regulatory Framework
9.6.4.4.4 Reimbursement Scenario
9.6.4.4.5 Argentina market estimates and forecast, 2020 - 2032
9.6.5 MEA
9.6.5.1 MEA gastrointestinal therapeutics market, 2020 - 2032 (Number of Patients by Type in Million)
9.6.5.2 South Africa
9.6.5.2.1 Key Country Dynamics
9.6.5.2.2 Competitive Scenario
9.6.5.2.3 Regulatory Framework
9.6.5.2.4 Reimbursement Scenario
9.6.5.2.5 South Africa market estimates and forecast, 2020 - 2032
9.6.5.3 Saudi Arabia
9.6.5.3.1 Key Country Dynamics
9.6.5.3.2 Competitive Scenario
9.6.5.3.3 Regulatory Framework
9.6.5.3.4 Reimbursement Scenario
9.6.5.3.5 Saudi Arabia market estimates and forecast, 2020 - 2032
9.6.5.4 UAE
9.6.5.4.1 Key Country Dynamics
9.6.5.4.2 Competitive Scenario
9.6.5.4.3 Regulatory Framework
9.6.5.4.4 Reimbursement Scenario
9.6.5.4.5 UAE market estimates and forecast, 2020 - 2032
9.6.5.5 Kuwait
9.6.5.5.1 Key Country Dynamics
9.6.5.5.2 Competitive Scenario
9.6.5.5.3 Regulatory Framework
9.6.5.5.4 Reimbursement Scenario
9.6.5.5.5 Kuwait market estimates and forecast, 2020 - 2032
Chapter 10 Gastrointestinal Therapeutics Market - Competitive Analysis
10.1 Recent Developments & Impact Analysis, by Key Market Participants
10.1.1 Ansoff matrix
10.1.2 Heat map analysis
10.1.3 Major Deals and Strategic Alliances Analysis
10.1.3.1 Joint Ventures
10.1.3.2 Licensing Agreements
10.1.3.3 Product Launches
10.1.3.1 Conferences and Campaigns
10.2 Company Categorization
10.2.1 Innovators
10.2.2 Market Leaders
10.3 Vendor Landscape
10.3.1 List of key distributors and channel partners
10.3.2 Key customers
10.4 Public Companies
10.4.1 Competitive Dashboard Analysis
10.4.1.1 Market Differentiators
10.5 Private Companies
10.5.1 List of key emerging companies
10.6 Company Profiles
10.6.1 AbbVie Inc
10.6.1.1 Company overview
10.6.1.2 Financial performance
10.6.1.3 Product benchmarking
10.6.1.4 Strategic Initiatives
10.6.2 AstraZeneca
10.6.2.1 Company overview
10.6.2.2 Financial performance
10.6.2.3 Product benchmarking
10.6.2.4 Strategic Initiatives
10.6.3 Takeda Pharmaceutical Company Limited
10.6.3.1 Company overview
10.6.3.2 Financial performance
10.6.3.3 Product benchmarking
10.6.3.4 Strategic Initiatives
10.6.4 Salix Pharmaceuticals
10.6.4.1 Company overview
10.6.4.2 Financial performance
10.6.4.3 Product benchmarking
10.6.4.4 Strategic Initiatives
10.6.5 Pfizer Inc
10.6.5.1 Company overview
10.6.5.2 Financial performance
10.6.5.3 Product benchmarking
10.6.5.4 Strategic Initiatives
10.6.6 Bayer AG
10.6.6.1 Company overview
10.6.6.2 Financial performance
10.6.6.3 Product benchmarking
10.6.6.4 Strategic Initiatives
10.6.7 Abbott
10.6.7.1 Company overview
10.6.7.2 Financial performance
10.6.7.3 Product benchmarking
10.6.7.4 Strategic initiatives
10.6.8 Janssen Global Services, LLC
10.6.8.1 Company overview
10.6.8.2 Financial performance
10.6.8.3 Product benchmarking
10.6.8.4 Strategic initiatives
10.6.9 Sun Pharmaceutical Industries Ltd
10.6.9.1 Company overview
10.6.9.2 Financial performance
10.6.9.3 Product benchmarking
10.6.9.4 Strategic initiatives
10.6.10 Cipla Inc
10.6.10.1 Company overview
10.6.10.2 Financial performance
10.6.10.3 Product benchmarking
10.6.10.4 Strategic initiatives
10.6.11 Gilead Sciences, Inc
10.6.11.1 Company overview
10.6.11.2 Financial performance
10.6.11.3 Product benchmarking
10.6.11.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers